帕博利珠单抗诱导一名95岁转移性黑色素瘤退伍军人患1型糖尿病。
Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma.
作者信息
Ng Damond B, Weinreb Jane, Rumrill Sara-Megumi
机构信息
Department of Medicine, David Geffen School of Medicine, Los Angeles, California.
Veterans Affairs Greater Los Angeles Healthcare System, California.
出版信息
Fed Pract. 2021 Nov;38(11):520-523. doi: 10.12788/fp.0191.
Abstract
Low C-peptide levels should prompt a high suspicion for immune checkpoint inhibitor-induced type 1 diabetes, and initiation of insulin therapy should be strongly considered.
摘要
低C肽水平应引起对免疫检查点抑制剂诱导的1型糖尿病的高度怀疑，并且应强烈考虑开始胰岛素治疗。
相似文献
1
Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma.帕博利珠单抗诱导一名95岁转移性黑色素瘤退伍军人患1型糖尿病。
Fed Pract. 2021 Nov;38(11):520-523. doi: 10.12788/fp.0191.
2
Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.免疫检查点抑制剂相关的糖尿病，与派姆单抗相关。
BMJ Case Rep. 2022 Jan 17;15(1):e245846. doi: 10.1136/bcr-2021-245846.
3
Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.患者接受派姆单抗治疗转移性黑色素瘤后出现多种免疫检查点抑制剂相关的自身免疫副作用。
J Oncol Pharm Pract. 2021 Jan;27(1):207-211. doi: 10.1177/1078155220921543. Epub 2020 May 9.
4
A case of pembrolizumab-induced fulminant Type 1 diabetes mellitus in breast cancer.一例帕博利珠单抗致乳腺癌暴发性 1 型糖尿病。
Immunotherapy. 2021 Apr;13(6):483-489. doi: 10.2217/imt-2020-0222. Epub 2021 Feb 25.
5
Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.糖皮质激素未能逆转一名转移性黑色素瘤患者因帕博利珠单抗继发的1型糖尿病。
BMJ Case Rep. 2016 Nov 23;2016:bcr2016217454. doi: 10.1136/bcr-2016-217454.
6
Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.帕博利珠单抗诱发的转移性黑色素瘤患者淋巴细胞性胃炎
Melanoma Res. 2018 Dec;28(6):645-647. doi: 10.1097/CMR.0000000000000502.
7
Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.回顾性分析接受派姆单抗治疗的初治斯洛文尼亚转移性黑色素瘤患者-真实世界经验。
Radiol Oncol. 2020 Jan 19;54(1):119-127. doi: 10.2478/raon-2020-0003.
8
A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.一例转移性黑色素瘤患者发生帕博利珠单抗诱发葡萄膜炎的罕见病例。
Pharmacotherapy. 2016 Nov;36(11):e183-e188. doi: 10.1002/phar.1839. Epub 2016 Oct 26.
9
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab.黑色素瘤患者使用派姆单抗治疗后发生自身免疫性内耳疾病。
J Immunother Cancer. 2016 Feb 16;4:8. doi: 10.1186/s40425-016-0114-4. eCollection 2016.
10
A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma.一例转移性黑色素瘤患者中与帕博利珠单抗治疗相关的严重糖尿病酮症酸中毒病例。
Diabetes Metab Syndr Obes. 2021 Feb 18;14:753-757. doi: 10.2147/DMSO.S297709. eCollection 2021.
引用本文的文献
1
Causes of death among patients with cutaneous melanoma: a US population-based study.美国人群中皮肤黑色素瘤患者的死因分析：一项基于人群的研究。
Sci Rep. 2023 Jun 24;13(1):10257. doi: 10.1038/s41598-023-37333-4.
本文引用的文献
1
Reporting of Immune Checkpoint Inhibitor Therapy-Associated Diabetes, 2015-2019.2015 - 2019年免疫检查点抑制剂治疗相关糖尿病的报告
Diabetes Care. 2020 Jul;43(7):e79-e80. doi: 10.2337/dc20-0459. Epub 2020 May 11.
2
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.帕博利珠单抗治疗晚期非小细胞肺癌患者的 5 年总生存结果：来自 I 期 KEYNOTE-001 研究的结果。
J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.
3
Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.免疫检查点抑制剂：一种新出现的胰岛素依赖型糖尿病病因。
BMJ Open Diabetes Res Care. 2019 Feb 13;7(1):e000591. doi: 10.1136/bmjdrc-2018-000591. eCollection 2019.
4
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.免疫检查点抑制剂相关内分泌不良事件的系统评价与荟萃分析
Horm Metab Res. 2019 Mar;51(3):145-156. doi: 10.1055/a-0843-3366. Epub 2019 Mar 12.
5
Evaluation of agreement between hemoglobin A1c, fasting glucose, and fructosamine in Senegalese individuals with and without sickle-cell trait.评价血红蛋白 A1c、空腹血糖和果糖胺在有和无镰状细胞特征的塞内加尔个体中的一致性。
PLoS One. 2019 Feb 15;14(2):e0212552. doi: 10.1371/journal.pone.0212552. eCollection 2019.
6
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.靶向免疫检查点的癌症免疫疗法的内分泌毒性
Endocr Rev. 2019 Feb 1;40(1):17-65. doi: 10.1210/er.2018-00006.
7
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.二甲双胍联合免疫检查点抑制剂（抗 PD-1/抗 CTLA-4）治疗转移性恶性黑色素瘤的疗效。
J Immunother Cancer. 2018 Jul 2;6(1):64. doi: 10.1186/s40425-018-0375-1.
8
Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.程序性细胞死亡蛋白-1 抑制剂诱导的 1 型糖尿病。
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3144-3154. doi: 10.1210/jc.2018-00728.
9
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors.附带损伤：检查点抑制剂诱导的胰岛素依赖型糖尿病。
Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002. Epub 2018 Jun 24.
10
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.免疫检查点抑制剂治疗患者免疫相关不良反应的管理：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.
Zotero 插件